CourageAS Biotherapeutics
PrivateLast Round
Joint Venture
Feb 14, 2025
Company Overview
CourageAS Biotherapeutics is a biotechnology company that develops non-viral genome editing therapies for the treatment of Angelman syndrome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CourageAS Biotherapeutics Comparables
Compare CourageAS Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MavriX Bio | 85% | |
| Biom Therapeutics | 84% | |
| GEMMA Biotherapeutics | 82% |
CourageAS Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Joint Venture | Feb 14, 2025 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 14, 2025
Funded by Couragene and Foundation for Angelman Syndrome Therapeutics.
CourageAS Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about CourageAS Biotherapeutics's valuation, stock price, and market status.
Is CourageAS Biotherapeutics a public or private company?
CourageAS Biotherapeutics is a private company.
What is the current stock price of CourageAS Biotherapeutics?
CourageAS Biotherapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is CourageAS Biotherapeutics worth (valuation)?
Valuation information for CourageAS Biotherapeutics is not publicly available.
Can I buy CourageAS Biotherapeutics stock?
CourageAS Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was CourageAS Biotherapeutics's last funding round?
CourageAS Biotherapeutics's most recent funding round was Joint Venture on February 14, 2025.
Who are the main investors in CourageAS Biotherapeutics?
Investor information for CourageAS Biotherapeutics is not publicly disclosed.
Will CourageAS Biotherapeutics IPO soon?
No public IPO plans have been announced for CourageAS Biotherapeutics.
How can I track CourageAS Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CourageAS Biotherapeutics's secondary market activity and sign up for updates.